Dr. Monk on Immunotherapy for Gynecologic Cancer

Bradley J. Monk, MD, FACOG, FACS
Published: Tuesday, Apr 18, 2017



Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

Immunotherapy is important in all types of gynecologic cancers, explains Monk. In cervical cancer, there is a randomized phase III trial about to begin regarding a checkpoint inhibitor.

Pembrolizumab (Keytruda) is an important regimen in microsatellite instability-high recurrent endometrial cancer for the second-line setting. This could potentially be the first checkpoint inhibitor approved for a gynecologic cancer, states Monk.
 


Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

Immunotherapy is important in all types of gynecologic cancers, explains Monk. In cervical cancer, there is a randomized phase III trial about to begin regarding a checkpoint inhibitor.

Pembrolizumab (Keytruda) is an important regimen in microsatellite instability-high recurrent endometrial cancer for the second-line setting. This could potentially be the first checkpoint inhibitor approved for a gynecologic cancer, states Monk.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x